I was successful in having the project known as Iron Boomerang referred to a Senate Inquiry. Iron Boomerang is a railway that is really a shopping cart on rails — bringing iron ore, rare earths and agricultural product from West Australia to North Queensland for easy export to markets around the world.
The iron ore will be combined with beautiful Queensland coal in a steel park in Queensland for domestic use, and for export to Asia and the Americas. The trains will then return to Western Australia loaded with coal, where another steel mill in the Pilbara will make steel for export to the subcontinent, the Middle East and Europe.
Estimates predict this project could add $200 billion (10%) to Australia’s GDP creating 50,000+ breadwinner jobs, while securing the nations’ future.
The Committee found in favour of the project and instructed Infrastructure Australia to contact the project sponsors to get started.
In today’s Senate Estimate session, Infrastructure Australia had the hide to say they ignored the request of the Senate Committee. As a result, this nation-building, jobs-rich project has not progressed. Watch this space!
https://img.youtube.com/vi/MEsvnDluY-A/hqdefault.jpg360480Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2023-10-25 11:00:572023-11-22 16:02:03Linking the Top End Coast to Coast by Rail
The Australian Renewable Energy Agency (ARENA) assures me that as Australia has very good sunshine and solar energy is the cheapest form of energy on the planet, we can expect to have cheap electricity. That’s nonsense because they don’t take into account all of the extra costs of firming, storage, extra transmission lines and general unreliability. Any Australian who looks at their electricity bill knows solar isn’t cheaper.
I was even more surprised to learn about the agency’s support of solar in renewable iron and steel manufacturing on a massive scale. The idea of such energy intensive industrial process being powered by cheap solar, which is currently too expensive and unreliable for Australian households, is pipe dream stuff.
This government is driving Australia off the cliff and is in the drivers seat essentially saying – “It’s not my job to think about the cliff, I’m just driving the car.” The idea of a net zero future with wind and solar providing base-load power and creating “green steel” is not real.
The net zero pipe dream is a nation killing fantasy that is already hurting the regions, ruining small business and driving up the cost-of-living all over Australia.
This is the second Senate Estimates I have raised questions about Chinese Communist Party contact points (or Chinese overseas police stations) in Australia. We know they exist and that this issue has been investigated and confirmed by mainstream media.
I asked Home Affairs, the department responsible for Australia’s security, why there is a CCP contact point office in Sydney. Home Affairs avoided answering – this from the department responsible for national security policy. What hope have we got? This is the same department that helps META censor accurate social media posts from Australians, yet it won’t discuss CCP activity within Australia.
I was told Home Affairs was not the correct agency to ask these questions and was directed to the Australian Security Intelligence Organisation (ASIO). The head of ASIO said he has no knowledge of a contact point in Sydney and referred me to the Australian Federal Police (AFP), who likewise stated that they had no evidence or information of this.
There must be a reason why they refuse to discuss this and are maintaining the secret.
Transcript below.
Transcript below.
Transcripts
Home Affairs
Senator ROBERTS: Yes. Given the general concern about the Chinese Communist Party’s global involvement in overseas affairs, in many countries’ affairs, why is there a Chinese contact point in Sydney? The contact point is a Chinese Communist Party-staffed office set up in a country outside China.
Mr Smyth: I would refer you to the Department of Foreign Affairs for matters in relation to that?
Senator ROBERTS: Well, you’re in charge of security.
Mr Smyth: I look after policy in relation to issues. But issues that go to bilateral relations with foreign governments or countries or their activities is a responsibility of the Department of Foreign Affairs and Trade.
Senator ROBERTS: I’m after program 1.2, national security and resilience, so I’ll continue.
Senator Watt: With respect, Senator Roberts, you can’t just ask any question that includes those words in it. There are particular departments that are better suited to answering certain questions, and I think DFAT is probably the best department to answer the questions you’ve just asked.
Senator ROBERTS: I would doubt that, Senator Watt, because this is a security issue.
Senator Watt: Sure, but we want to make sure that you get the very best possible answers. You’ve already heard from the officials that DFAT is probably best placed, and they’ll be up on Thursday.
Senator ROBERTS: The AFP deputy commissioner investigations, Reece Kershaw, addressed this matter in a Senate estimates hearing in November 2022. He said that he did not believe the Sydney contact point was active, without going into further detail. So these questions are being asked to update the current situation. Is there still a CCP supported contact point in Sydney? That’s a yes or no answer. It doesn’t need to upset anyone.
CHAIR: Senator Roberts, the AFP will be appearing a little bit later today. If you’ve got questions for them or are following up from answers that they’ve given at previous estimates, they will be available for you to ask those questions then.
Senator ROBERTS: I’m stunned that the Department of Home Affairs cannot face questions about security?
Senator Watt: That’s not a fair way to put it.
Senator ROBERTS: It is true.
Senator Watt: That’s your take on it, Senator Roberts. We’ve tried to assist you by—
Senator ROBERTS: Let the people of Australia decide on what their take is.
Senator Watt: We’ve tried to assist you by telling you the two different groups you could put those questions to. We’re all going to be here all week and there are opportunities for you to ask those questions.
Senator ROBERTS: What’s the role of Home Affairs with regard to national security and resilience? Minister?
Senator Watt: I’ll suggest that the deputy secretary in charge of that area answers your question, Senator Roberts.
Mr Smyth: In relation to resilience, we have a task force that was established in November 2022, and that’s to better position Australia for what we see as a significant set of risks and challenges that it faces across the full spectrum of national and human induced crises. The task force leads on national resilience policy and strategy. That ensures that the Commonwealth has the necessary policy, legislation and capability to manage what is really an increasingly complex and cascading set of concurrent national crises in the current geostrategic and geopolitical environment. We provide advice to government around issues in relation to national security. We look after national security policy. We look after legislation for intelligence services. We look after countering foreign interference policy, terrorism policy et cetera.
Senator ROBERTS: Counter and foreign interference policy—that’s what I’m talking about.
Mr Smyth: And we do that in collaboration with other portfolio agencies.
Senator ROBERTS: I’d like to know your role in that collaboration.
Mr Smyth: My role is as the National Counter Foreign Interference Coordinator.
Senator ROBERTS: What would be your role in knowing whether or not there’s a CCP-supported contact point in Sydney?
Mr Smyth: I’d have to take that question on notice. I think the evidence that was given to you by Commissioner Kershaw was that that is not an active—
Senator ROBERTS: I’d like to know what it is now.
Ms Foster: I think that the difference perhaps is that Mr Smyth is responsible for the overall policy and coordination, but operational issues will typically fall within the purview of the operational agency which is why the Australian Federal Police is best placed to answer questions about current operations.
Senator ROBERTS: Wonderful! Before you start getting into policy—unlike climate change, where there’s no data, despite driving that policy—what is the purpose of the Chinese Communist Party contact point in Sydney? What is its purpose?
Mr Smyth: I would refer you to the AFP in relation to the evidence that has been previously given by Commissioner Kershaw.
Senator ROBERTS: I want to know what it is now. That was 12 months ago.
Ms Foster: Yes, Senator, and that’s an operational issue, which Senator Kershaw is well placed to answer, and he will be appearing later tonight.
Senator ROBERTS: I want to know what your take on it is, because we’re trusting you with our security.
Ms Foster: I’ve just made a distinction between our role in providing the overall policy framework and coordination and the role of individual operational agencies to manage specific operational issues. I think it’s evident from the fact that the evidence last time came from Commissioner Kershaw that this is an operational issue which the AFP is best placed to deal with.
Senator ROBERTS: What’s your policy for handling the Chinese Communist Party contact points, and what’s the basis of that policy?
Mr Smyth: The issues that relate to that, I think, are best referred to the Counter Foreign Interference Taskforce, which is an ASIO and AFP led taskforce that deals with operational matters in relation to foreign interference activity on Australian soil.
Senator ROBERTS: I’ll acknowledge that you’re talking about operations with other people. I want to know what the basis for your policy is in regard to the Chinese Communist Party contact points in Sydney, because initially they weren’t existing and then we find out they do.
Mr Smyth: Where foreign governments seek to interfere in the democratic process of Australia, we take an interest, but those issues relate more to operational matters for taskforce agencies. In relation to the contact point that you’re referring to, I’d have to take on notice any specific information that we have that resides in this portfolio.
Senator ROBERTS: Okay. That’s two questions you’ve taken on notice. Are there Chinese police officers working out of the premises? You can take that on notice. And are—
CHAIR: Senator Roberts!
Mr Smyth: That would be an operational matter for the taskforce members and also a matter potentially for the Department of Foreign Affairs and Trade.
Ms Foster: Senator, we’re not seeking to be unhelpful. It’s just not helpful to you if we take something on notice which we’re then going to refer to someone else.
Senator ROBERTS: Are there any concerns of the security agencies about potential breaches of Australian national sovereignty?
Ms Foster: That would have to be addressed to the security agencies.
Senator Watt: ASIO will be on later today as well, Senator Roberts. There are opportunities for you to ask these questions. It’s just that they’ve got to go to the people who can answer them.
Senator ROBERTS: I’d would like to know that Home Affairs knows something about this. Should Chinese people living in Australia be concerned? You’re in charge of security.
Mr Smyth: Again, I’ll refer you to previous answers that we’ve given.
Senator ROBERTS: Thank you.
CHAIR: Senator Roberts, are those all the questions you have?
Senator ROBERTS: Thanks, Chair.
Australian Security Intelligence Organisation (ASIO)
Senator ROBERTS: Thank you, Mr Burgess and your staff, for being here. I asked a question of Home Affairs, and they said to come here and also AFP. Given the general concern about Chinese Communist Party global involvement in overseas affairs, why is there a Chinese contact point in Sydney? A contact point, I’m sure you know, is a Chinese Communist Party staffed office set up in a country outside China.
Mr Burgess: I’m not aware of a Chinese contact point in this country other than the official consulate and embassy presence.
Senator ROBERTS: The Australian Federal Police deputy commissioner of investigations, Reece Kershaw, addressed this matter in a Senate estimates hearing in November 2022. He said he did not believe the Sydney contact point was active, without going into further details. These questions I’m going to ask are to update the current situation. You’re not aware of it, so what is the purpose of a CCP contact point?
Mr Burgess: I can’t comment about the purpose of something I’m not aware of. What I will say is my agency does consider and look for signs of foreign interference, and it’s more the behaviour we’re focused on in terms of anyone in this country that might be here doing something which is against our national interest, represents a threat to security and is not publicly declared.
Senator ROBERTS: Would it be something you’d investigate if it wasn’t a threat necessarily to Australian security but a threat to the security of Chinese citizens or former Chinese citizens?
Mr Burgess: Anyone in this country gets our protection.
Senator ROBERTS: Good. As I said, Reece Kershaw addressed the matter and said he didn’t believe it was active, without going into further detail. You can’t tell me how long it’s been in operation? You can’t tell me, a year later, whether there are Chinese police officers working out of the premises?
Mr Burgess: I would stand by my judgement that there is not a Chinese contact point in this country.
Senator ROBERTS: Are there concerns at the security agencies about potential breaches of Australian national sovereignty?
Mr Burgess: Every day in my line of business.
Senator ROBERTS: Do you surveil any threats from the CCP in this country that could affect Chinese residents or Taiwanese residents?
Mr Burgess: I do not talk about operational matters publicly.
Australian Federal Police
CHAIR: Thanks, Senator Scarr. Against my better judgement, Senator Roberts has got two minutes. That probably equates to two questions, and we thank you for your brevity.
Senator ROBERTS: Thank you for appearing tonight. The 60 Minutes program broadcast on 18 June this year—an investigative story—showed interviews with several Australian citizens who had been intimidated by Chinese authorities and showed proof of the existence of at least one Chinese overseas police station in suburban Sydney. What actions have been taken by the AFP with whom the information was shared?
Mr McCartney: I think we’ve been asked this question a number of times during past Senate estimates and I think we’ve been consistent. In terms of the construct of a Chinese police station operating in Australia, I also heard the Director-General of ASIO state today that we’ve got no evidence or information on that. But, having said that, is Chinese foreign interference a threat? Yes, it is, and we continue to work very proactively with ASIO and other agencies in relation to that space.
Senator ROBERTS: This is my last question. The Australian Federal Police deputy commissioner of investigations, Reece Kershaw, addressed this matter in Senate estimates hearings in November 2022, I understand. He said he did not believe the Sydney contact point was active, without going into further detail. These questions are asked to update the current situation.
Mr Kershaw: Senator, I’m the Commissioner of the AFP. I think you called me ‘deputy’. You’ve demoted me!
Senator ROBERTS: I have a lot of respect for the AFP; believe me. And I’m pleased you can see it with a sense of humour.
Mr Kershaw: So what was the end of a question?
Senator ROBERTS: Reece Kershaw said that the Sydney contact point was active, without going into further detail. I was going to ask more questions.
Mr McCartney: Senator, I think it was actually me who said that at the last Senate estimates. I would go back to my first answer: there’s no information that indicates that a Chinese police station is operating in Sydney, and that’s a position that’s supported by ASIO.
Senator ROBERTS: Thank you very much, Chair.
CHAIR: Thanks, Senator Roberts. We appreciate you keeping to your word. That’s all the questions we have for the Australian Federal Police. Thank you, Commissioner.
https://img.youtube.com/vi/dtUwEP53odo/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2023-10-25 07:44:032023-11-03 14:20:51CCP Office in Sydney? Nothing to See Here!
Principal Medical Officer at the Civil Aviation Safety Authority (CASA) has been absent during our previous senate estimates sessions despite my requests for her presence.
I asked her questions about her other roles and responsibilities, including her role as supervising GP and her other board positions. I also asked about her knowledge of pilot adverse events and what research underpins her position that such adverse events as myocarditis are predominantly caused by the COVID infection rather than the COVID injections.
It’s been a long wait to ask these questions of Dr Manderson and her staff appeared anxious to shield her from my line of inquiry. What do they have to hide?
The $100-$200 million tunnel-boring machine known as Florence has been bogged in muddy water on soft ground for a year.
I followed up on previous estimate questions, where I was categorically lied to by bureaucrats who were trying to cover up this expensive and embarrassing disaster.
Why is the government allowing executives from the Snowy Hydro Authority to deliberately mislead the committee about the main tunnel being blocked by a boring machine that has not moved in a year? Why did Snowy 2 executives and the government cover up the toxic gas in the tunnel that is coming from the chemicals used to unsuccessfully free Florence?
The cost has now blown out to $12 billion, with another $5 billion needed to carve a 50 metre wide easement through the Snowy Mountains National Park. This is to build transmission lines to take the power into the grid and to upgrade, to carry 2200 MW of power for 20 minutes in the morning and evening peak, which is all Snowy 2.0 will generate.
I look forward to receiving the answers to my Questions on Notice for the Minister.
Transcript
Senator ROBERTS: Thank you for being here again today. Mr Whitby, in the November 2022 estimates, I asked you:I note that the tunnelling machine Florence was bogged up near Tantangara Reservoir. Can you confirm how long it was bogged and confirm that it’s now back in operation? The answer you gave was: The tunnel-boring machine hasn’t been bogged. It encountered soft ground, which we expected. We have been progressing the tunnel-boring machine through that zone with care and diligence. In February 2023, I was reassured Florence was not bogged, and, in May 2023, was advised it would progress shortly. Minister: today, the ABC published photos of Florence clearly in mud and water in a story that says it was flooded in and unable to function from the moment it hit the soft ground a year ago. It moved a matter of metres. Further, the article goes on to say Snowy Hydro authority knew it was bogged even as they testified in senate estimates that it was not. The authority was covering up the machinery to progress Florence. A slurry machine that lays down a base for the machine to travel over was not ordered when the waterlogging was discovered. It was only ordered when Florence became bogged. Why is the government allowing the authority to deliberately mislead the committee?
Senator McAllister: Thank you for the question, Senator Roberts. I don’t quite recall the evidence being provided in the terms that you suggest in your question. But I confess I don’t exactly remember all of the testimony that was provided at all of the estimates. I will invite Mr Barnes to respond.
Senator ROBERTS: Minister, before you do, were they lying to you? When did you know about the machine being bogged?
Senator McAllister: I will take that on notice. You will understand that I don’t have all of the communications between the authority and shareholder ministers, so I will see what I can provide.
Senator ROBERTS: I would like to know when you found out the machine was bogged, if you made inquiries beforehand, were they lying to you, and whether or not you were misled.
Senator McAllister: I will take those questions on notice.
Mr Barnes: Obviously, there are many engineering terms, but bogged, paused or stuck, all have subjective definitions. There has been no point since Florence encountered this incredibly soft and wet ground in November 2022 that the machine has not been able in some way to move forward. In fact, as part of its stabilisation and commissioning of the slurry treatment plant since December 2022, it has in fact moved 10 metres as part of that activity, so it is not bogged; it is able to move. In May I apologised for my perhaps optimism regarding the ability to get Florence moving at pace again. The full story on the slurry treatment plant is that Florence is going to hit what we know to be naturally occurring asbestos about seven kilometres into its journey.
Senator ROBERTS: Naturally occurring what?
Mr Barnes: Asbestos.
Senator ROBERTS: Do you mean naturally in the strata?
Mr Barnes: Yes, and the slurry treatment plant is designed to handle those conditions. The incredibly soft ground it hit early in its journey was not predicted at that stage, so the slurry treatment plant, which was always envisaged—just not envisaged that quickly—was ordered and started to be designed as early as December 2022. It is now complete, commissioned. Once we receive an approval from the New South Wales Department of Planning and Environment, we will be able to move forward.
Senator DAVEY: I agree with your recollection, Senator Roberts. Mr Barnes, you spoke in May about the fact that the slurry treatment plant was coming. I took it from that evidence that it would be activated sooner rather than later, but are you saying it still hasn’t been turned on?
Mr Barnes: To jog your memory, I think I said weeks, not months. I should have said months, not weeks. It wasn’t a mistake, it was my optimism at the time. The physical works to get the slurry plant complete and Florence able to move. We’ve all progressed. What I underestimated was the process with which to go through the approval process, given the sinkhole that formed in December is just outside our construction boundary.
Senator ROBERTS: Mr Barnes, could you give me on notice the movement of the machine, in metres, between November 2022 and February 2023, between February 2023 and May 2023, and from May 2023 to now?
Mr Barnes: Yes.
Senator ROBERTS: Thank you. Minister, it seems on the face of it that this is government misinformation covering up a massive failure. I’m not blaming you entirely for that, because this whole thing was started under Malcolm Turnbull as prime minister and Scott Morrison as prime minister. There was no fully disclosed business case. It was heavily redacted. There was no cost-benefit analysis done. The whole thing is based on a false premise. This is what happens when the top is rotten. I’m not referring to you as being rotten, Minister; I’m referring to the project when it was first given the go-ahead. But you’re now carrying the can.
CHAIR: Is there a question?
Senator ROBERTS: Yes. Minister, what questions are you asking about the rest of the project, because this is serious stuff?
Senator McAllister: You are right in this regard: the project as first announced by the Turnbull government does not reflect the dimensions and characteristics of the project as we now understand it. Some of those changes and issues were known to the previous government and not revealed. Minister Bowen has made it very clear how disappointed he was when he came to government and discovered that aspects of the project, including significant delays in cost increases, had not been communicated. As I indicated earlier in my evidence, when Mr Barnes was appointed, the expectation from the shareholder ministers was communicated very clearly to the board and, I understand, through the department to Mr Barnes that we wanted to see this project back on track. We wanted the new management to examine it and provide advice about how to get it back on track. It took some time. It wasn’t possible to do that in weeks; it has taken Mr Barnes some time. When that advice was provided, it was to the Minister, who then sought to communicate it directly to the Australian public. These are complex projects. We accept that. We have noted a constructive tone and a more open approach to communication from the engagements we are presently having with Snowy Hydro, and we hope to see this project—which, as I indicated, is an important project for the energy system and the Australian people—back on track.
Senator ROBERTS: Let’s move to something else that the government has lied about. This might not be ministerial staff or the ministers themselves, but we know that the agency has lied about the toxic gas in the shaft coming from isocyanate, used to strengthen the ground in the absence of proper machinery—the slurry machine. That was more government misinformation, wasn’t it, Minister?
Mr Barnes: I’m happy to talk to this. You are referring to an incident that occurred in early July. When polyurethane foam, which is sometimes used in front of the tunnel boring machine, comes into contact with water it can create isocyanate gas. It did so. The incident was reported quickly, access to the site was restricted, additional personal protective equipment was provided and monitoring was put in place.
Senator ROBERTS: What was that personal protective equipment?
Mr Barnes: You can do positive-pressure face masks which stop any gases entering.
Senator ROBERTS: Does that involve carrying air or oxygen?
Mr Barnes: No. I don’t how the reverser flow works, but you picture the large face masks with a positive flow meter. They have a filter. I don’t know the details of how those machines work, but they do protect the individual. We have actually stopped using the polyurethane foam and reverted to grout on that.
Senator ROBERTS: So lives are at stake?
Mr Barnes: Absolutely. This is a complex project with many hazards.
Senator ROBERTS: And the economy is at stake if this project doesn’t live up to nameplate design. How much is Florence worth, and who pays if you can’t get it out or if it comes out as scrap?
Mr Barnes: Florence is not identified as a single item in the project line, but between $100 million and $200 million would be an estimate of a tunnel boring machine. But Florence is able to progress its journey once we receive the necessary approvals.
CHAIR: We’ll need to rotate the call, Senator Roberts. Do you have a final question? We can come back to you.
Senator ROBERTS: In May I asked about the updated cost, and Mr Barnes replied, ‘We haven’t got an updated cost here and will provide that in months.’ Your updated cost is now $12 billion? Is that it?
Mr Barnes: That’s correct.
Senator ROBERTS: Does that include two major expenses: transmission lines to get the power in and out and the ongoing cost of Florence still being bogged?
Mr Barnes: It is the cost to complete the project to the transmission lines at the power station, including all action necessary to complete the head race tunnel, which is where Florence is.
Senator ROBERTS: So any additional transmission lines needed to take the power out are not part of that project cost?
Mr Barnes: We have one transmission connection from the power station up to the grid, which Snowy Hydro pays for on an ongoing tariff.
Senator ROBERTS: My understanding is that the current transmission lines will not be adequate after Snowy 2 comes in.
Mr Barnes: For snowy 2 to get its full potential, there is an extension to the transmission grid required.
Senator ROBERTS: Thank you. So the total cost of this project—
CHAIR: We need to move on, Senator Roberts. We need to rotate the call.
Senator ROBERTS: Okay.
Senator McAllister: Senator Grogan, I took on notice a series of questions from Senator Roberts. I had previously indicated that these were questions for shareholder ministers and I would take them on notice on their behalf. I just want to clarify that that’s also what you were seeking in the other questions that you put to me later on?
Senator ROBERTS: I’m happy to get an answer from the government ministers. It doesn’t have to be you; just the person in charge would be perfect.
In the May/June Estimates, I asked questions about former MP Craig Kelly being booted off Facebook (META) for posting alleged misinformation about COVID, which turned out to be accurate. Initially, Home Affairs denied involvement in censoring parliamentarians, however it transpired they were involved. These questions are following up to those asked in the previous Senate Estimates, where we have confirmation that Home Affairs censored a sitting Parliamentarian.
An international advertising agency was employed to identify posts that were contrary to the government’s narrative on COVID. Over $1,000,000 of taxpayers’ money was paid to M&C Saatchi to act as the thought police against the Australian people.
These referrals enabled social media companies to make what Home Affairs calls ‘their own determinations’ about flagged posts and accounts should they go against the platform’s own guidelines.
This is significant. Home Affairs claims it’s not in the business of censorship, but what else would you call such an arrangement? If the Labor government legislates its bill to combat misinformation and disinformation, we will see even more of this dystopian censorship.
Judging by the strained and carefully worded answers in this video, Home Affairs would like us to believe it had no influence on the censorship of Australians online during the COVID response. We’re not so naïve to believe their collaboration with social media companies such as META, which resulted in de-platforming an elected member of parliament, was anything other than authoritarian overreach.
Transcript
Senator ROBERTS: Thank you all for being here today. At the last Senate estimates, I was given many assurances by the witnesses from the Department of Home Affairs that no parliamentarians would have been referred for censorship under your COVID-19 program. We now know that that was false. The Department of Home Affairs did refer the post of a sitting parliamentarian to the social media companies for censorship, and we’re meant to believe that the senior witnesses at this table knew nothing about it. Either the Senate was misled or the witnesses at this table do not actually know what’s going on in your department, as they refer parliamentarians for censorship. Is your department out of control?
Ms Foster: Our department is happy to respond to your question. Mr Smyth can take you through the detail.
Mr Smyth: I think, as referenced in previous hearings, the department is not in the business of censoring. We referred posts to social media platforms to take action at their discretion as to whether or not they felt that particular posts breached their service standards. I know that, from the previous hearings in relation to whether or not there were posts that were from particular members of parliament, the secretary at the time said that he would be surprised. You are quite correct that there were referrals for a particular member of parliament that were made. They shouldn’t have been made, and the department has looked at its processes. But we do not now engage in any of the same activity. That activity ceased in late May of this year.
Senator ROBERTS: So you’re enabling censorship and you were serving the social media giants—Meta, in particular—with the provision of their own services.
Mr Smyth: As I previously said—
Senator ROBERTS: Is that correct?
Ms Foster: No, that’s not correct, Senator.
Mr Smyth: we are not in the business of censoring.
Senator ROBERTS: But you enable censorship.
Ms Foster: No, we provide referrals to social media companies in order that they can decide whether or not the activity meets their own service standards.
Senator ROBERTS: So you’re providing a service to Meta. Do you charge them an invoice?
Mr Smyth: No. The issues that were at play at the time related to public health and safety. We operated on advice and criteria that were provided to the department from the Department of Health. That was then assessed through a service provider that we had— M&C Saatchi. The department then reviewed the references from M&C Saatchi as to whether or not they were likely to have been in breach of the service standards of particular platforms. The platforms were then informed of that, and they made their own decisions.
Senator ROBERTS: Isn’t Meta big enough to look after itself? Can’t it do its job? Are you helping them?
CHAIR: Senator Roberts, I want to draw you back to the question—as being relevant to outcome 1.
Senator ROBERTS: They referred it, it seems to me, Chair—
CHAIR: Yes, absolutely.
Senator ROBERTS: with the intent of taking it down.
CHAIR: The relationship is obviously relevant. Direct questions about Meta might be better directed to them and is outside of outcome 1’s relevance.
Senator ROBERTS: You referred it with the intent of it being taken down, Mr Smyth.
Mr Smyth: No, we referred it with an intent as to whether or not the platform could determine whether it breached their own service standards.
Senator ROBERTS: Are you in the business of helping large global multinationals conduct their own affairs? Surely—
Mr Smyth: We’re in the business of looking after public health and safety, and it was in the middle of a global pandemic where a lot of people were dying.
Senator ROBERTS: Have you received legal advice on whether your department has breached the implied freedom of political expression with this program?
Mr Smyth: No.
Senator ROBERTS: Why not? This is pretty significant.
Mr Smyth: Because the posts that were referred to were a decision of the platforms themselves as to whether or not they would take any action.
Senator ROBERTS: The department has paid more than a million dollars to M&C Saatchi for their part in this COVID-19 censorship referral program. Did M&C Saatchi determine what was misinformation or did the department? Did M&C Saatchi or the department determine whether or not it complied with Meta’s guidelines?
Mr Smyth: The funds that were paid to M&C Saatchi from March 2020 to July of last year were $256,000 in relation to the COVID information. There was a previous contract that was already in place that was around $500,000-plus.
Senator ROBERTS: I have a question on notice—BE23-193—about M&C Saatchi payments. This is your response:
Of these payments, World Services Australia (trading as M&C Saatchi) has been paid a total of $1,000,911 (GST inclusive) from 1 July 2019 to 31 May 2023 for their work to produce analytical reporting on COVID-19 malign information in the Australian social media environment.
I jump in there to say that some of what is known as ‘malign’ is now vindicated.
This can be broken down into the following payments by financial year:
2020-21: $757,470 – that’s three-quarters of a million.
2021-22: $127,908
2022-23: $115,533
That’s a lot of money going to an international advertising firm.
Ms Foster: You’ve asked us to take that on notice. We will be happy to do so.
Senator ROBERTS: This was your reply.
When people said they thought the government was censoring posts around COVID, that wasn’t a conspiracy theory; it was actually true. You were helping Meta to censor posts that have now proven to be correct.
Ms Foster: I think the officer has provided this evidence a couple of times already. We were referring posts to social media companies for their own decision.
Senator ROBERTS: In accordance with their guidelines—helping them out? Right. Minister, the pending misinformation/disinformation bill legitimises suppression and censorship with no definition of truth. It relies on ministers’ rules. I want to read a quote from Mr Pezzullo—
Senator Watt: I don’t think I would agree with your characterisation.
Senator ROBERTS: There’s no definition of ‘truth’ in your pending bill.
Senator Watt: The entire statement you made—I wouldn’t agree with your characterisation of this bill. I think it’s a bill designed to deal with an increasingly important issue in society, which is the use of social media platforms to spread misinformation and disinformation. That’s what I would say this bill is about.
Senator ROBERTS: But the government is exempt. The mouthpiece media, the mainstream media, is exempt. Social media is not and individual citizens are not. How can that be fair? I will read from Mr Pezzullo in the last estimates:
If we’ve inadvertently—and it would be inadvertent—made a referral of a sitting member or a senator, then I would find that regrettable because, in a sense, you’re held to account by your peers and by your electors; it’s not my job to hold you to account.
Since when has it become the government’s job to hold senators to account on what they say?
Senator Watt: Mr Smyth has already acknowledged—I can’t remember the exact words he used, but it was to the effect that it was regrettable that this had occurred on one occasion. The department looked into that issue after it was raised at the last estimates. Mr Pezzullo said that it would be regrettable if it had occurred, and Mr Smyth has already addressed that this morning.
Senator ROBERTS: Let me make it clear. I’m not talking about the department anymore. I’m talking about Labor’s pending misinformation/disinformation bill.
CHAIR: If that’s what you’re doing, that’s not relevant to outcome 1. I’ve given you—
Senator ROBERTS: I’m using—
CHAIR: No. Senator Roberts, I’ve given you two direction about asking relevant questions in this section. If you don’t have relevant questions then we do need to share the call.
Senator Watt: Chair, I make the point that not only are Senator Roberts’s questions not relevant to this outcome; they’re not relevant to this committee, because this bill that he is referring to is actually being led by the Minister for Communications. Perhaps Senator Roberts could take up those questions at that estimates hearing.
Senator ROBERTS: He will do.
Senator Watt: That is on now—today.
CHAIR: It is happening today and tomorrow, so you do have an opportunity to ask those questions to the appropriate officials.
Senator ROBERTS: Thank you, Senator Watt. Thank you, Chair.
https://img.youtube.com/vi/CR_KYCMyru0/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2023-10-24 14:12:462023-11-08 09:02:21Home Affairs Collaborated with Social Media During COVID
In Senate Estimates, Professor Brendan Murphy, former Chief Medical Officer for the Australian Government and now Health Secretary, rejected the suggestion that the TGA ever took a position on vaccine mandates.
You can listen to him saying here that the government only supported mandates in limited circumstances earlier in the COVID injection roll-out. He says they were only needed in health, disability and aged care settings due to their high vulnerability.
National Cabinet had no strong position on community-wide mandates. Professor Murphy claims that everyone, including other departments and jurisdictions, took their own position. The TGA did not promote the COVID injections or mandates. Incredible!
The TGA authorised Moderna’s injection for young children with co-existing health conditions despite the fact the study is only being conducted in healthy children. That study is also not yet completed. ATAGI’s guidance is that the ‘vaccine’ is recommended ONLY for high-risk children with a comorbidity. Under questioning, the TGA admits it does not require patient level data and relies on a dossier from the sponsor (the pharma company). The ATAGI advice was that this shot be reserved for use in ‘at-risk’ children, i.e those with immuno-compromising pre-existing conditions.
I asked the TGA about reporting performances in the DAEN database of adverse events including fatalities. I wanted to know whether adverse event notifications were higher in those parts of the country where reporting is required compared to those without mandatory reporting. I’m advised that reporting rates are not higher in the jurisdictions where it is obligatory to report. The TGA has advised that consumer reporting of adverse events directly to the TGA increased by 28-fold in 2021 compared to 2020. Similarly, health professionals submitted nearly three times as many adverse event reports to the TGA in 2021 compared to 2020.
Strict independence of scrutiny for these products is clearly needed and is now being called for by a highly regarded epidemiologist.
Mortality figures for cancer are higher since the injections were introduced. The COVID products were not tested for carcinogenic properties simply because those responsible have taken the position that the substances involved don’t warrant such studies. The TGA did review Pfizer product on paper only for genotoxic and carcinogenic potential. In its dossier, Pfizer justified the absence of studies into cancer risk based on the exposure threshold concept. However, there is an absence of repeat dose toxicity data and the assessment of the stimulation of cytokine release.
Pfizer’s dossier, as sponsor of the product, adequately justified the authorisation of its use in Australia by the TGA, and so we joined what former Minister for Health, Greg Hunt, called the largest human trial and the largest vaccination trial that the world has ever engaged in.
Transcript
Senator ROBERTS: Let’s talk about approval of paediatric COVID vaccines. The TGA approved the Moderna COVID paediatric vaccine on 19 July last year for children aged six months to five years. According to your website, this was based on the results of the KidCOVE clinical trial run by Moderna in the USA and Canada. The approval was for all children, but ATAGI’s guidance is that the vaccine is recommended only for high-risk kids having one of a list of serious comorbidities. Is that correct?
Dr Langham: I believe so. I would have to check the current ATAGI guidance, though. I can take that one on notice.
Senator ROBERTS: Thank you. The KidCOVE clinical trial is listed on clinicaltrials.gov as ‘a study to evaluate the effectiveness of Moderna’s vaccine in healthy children’—healthy children—’aged six months to 12 years’. On what basis did TGA authorise the use of a vaccine, tested on healthy kids, for use in Australia on high-risk kids with serious comorbidities?
Dr Langham: What we’ve learned throughout the pandemic is that the disease of COVID is most damaging to those with other comorbidities, and particularly people who have immune systems that don’t work well. Our recommendation, or the recommendation of ATAGI and the recommendation of the TGA, would have been to be able to support young children with precisely those conditions by demonstrating that the virus was safe and efficacious in a healthy population.
Senator ROBERTS: The study was to evaluate effectiveness of Moderna’s vaccine in healthy children, yet you’ve approved it for children with comorbidities—no basis.
Dr Langham: Again, it is the sort of thing that can be extrapolated. It was very important to be able to provide a protective therapy for young Australians who were at risk of serious illness from COVID-19.
Senator ROBERTS: You just extended the study into a completely different field without testing?
Prof. Murphy: You can’t do the clinical trials—those trials have to be done in healthy children. You wouldn’t be able to do that first in-population trial in people with severe underlying diseases. You’d have to get healthy volunteers. The ATAGI advice considers all of the other risks of COVID as well. The safety can be shown in healthy people but the ATAGI advice is relevant to the risk of severe COVID. There’s no disconnect there.
Senator ROBERTS: Your approval was in July 2021. That clinical trial finishes in November 2023, so it is not even finished yet. The TGA must have worked from interim documents. Did the TGA evaluate the patient-level data, or did you just take Moderna’s word for it, like you took Pfizer’s word for it?
Mr Henderson: The Moderna vaccine was approved through the provisional pathway, which is a wellestablished pathway. It was an established pathway before the pandemic. That allows for approval based on interim clinical data, and data will be supplied on a rolling basis over a period of time.
Senator ROBERTS: Did you evaluate the patient-level data before you approved it?
Mr Henderson: We have answered questions in relation to patient-level data. At the TGA, we do not require patient-level data. We do require clinical data that is sufficient evidence from the sponsor of the vaccines.
Senator ROBERTS: So you relied on sponsors of the vaccines?
Mr Henderson: We relied on the dossier provided by the sponsor, with clinical data provided.
Senator ROBERTS: Would this be misfeasance on the part of the TGA?
Mr Henderson: Sorry, Senator, I’m not sure—
Senator ROBERTS: Let’s move on. Quality of reports in the DAEN: the DAEN reports can come from medical practitioners and also the general public. How many of the reports of deaths from COVID vaccines recorded by DAEN came from members of the public and how many from medical practitioners?
Mr Henderson: I don’t have those exact numbers with me. I will take it on notice.
Senator ROBERTS: Why is the first question you ask, when a person makes a report: ‘Are you a medical practitioner or a member of the public?’
Mr Henderson: It is to allow us to have as rich a dataset as we can.
Senator ROBERTS: Why is the first question that one?
Ms Duffy: It allows the triaging of the subsequent questions as you go through the form.
Senator ROBERTS: Checking these reports—my staff have checked the reports—suggests there is a waiting room at the DAEN database holding reports that have been made but not yet checked and registered, which seems logical. How many reports of COVID vaccine harm are waiting to be checked? How many of those are reports of death or serious injury?
Mr Henderson: Again, I don’t have those numbers with me. I will take that on notice.
Senator ROBERTS: Thank you. Were more reports to DAEN made by states with mandatory adverse vaccine effect notifications—which I think is New South Wales, Queensland and Western Australia, which is only 62 per cent—as against states without mandatory reporting of vaccine harm?
Mr Henderson: Senator, could you repeat the question?
Senator ROBERTS: Was there a higher proportion of reports of adverse events from states with mandatory adverse vaccine effect reporting notifications?
Mr Henderson: I would have to take that detailed question on notice.
Senator ROBERTS: There is now a call for a vaccine safety office from an epidemiologist. He is pretty highly regarded, from my understanding. He is calling for independence in the scrutiny. When we have a provisionally approved medication, surely, it’s even more important to have a very strict reporting of adverse events?
Mr Henderson: We have a very comprehensive and rigorous safety monitoring system at the TGA. We use a number of mechanisms to look for safety signals, as well as talking to our international regulator colleagues and sharing information in relation to safety issues with the vaccines.
Senator ROBERTS: Have you done any testing on what percentage of doctors and the public are reporting adverse events?
Mr Henderson: No, we haven’t done that study. I will take that on notice.
Senator ROBERTS: Let’s go to carcinogenicity of the vaccine. The European Medicines Agency, EMA, had a 140-page assessment report for the Pfizer vaccine. On page 55, it says: No genotoxicity nor carcinogenicity studies have been provided. It then says: The components of the vaccine are lipids, an mRNA, which are not expected to have genotoxic potential. The carcinogenicity part of that statement was skated straight over. I want to ask you about that. Did you receive any genotoxicity or carcinogenicity studies in support of the Pfizer application?
Mr Henderson: I do not believe that we did, Senator.
Senator ROBERTS: The words ‘carcinogenicity’ and ‘cancer’ do not appear in your 42-page assessment report. Did you review the Pfizer product from the perspective of cancer?
Mr Henderson: I believe there was no need for that. I will take it on notice.
Senator ROBERTS: According to the data from the Australian Bureau of Statistics, in their latest release of the provisional mortality statistics, we know that it under-represent deaths—this was from the head of the ABS the other night—by 15 per cent because it does not include autopsy reported deaths, only doctor reported. The figures for provisional mortality from cancer were as follows: based on average for January-February over the last four years, 3,637; January- February cancer deaths in 2023, 3,803—plus 15 per cent; and for 2021 it was 3,816. Both years are above trend. It should be remembered that trend includes autopsy deaths and the provisional mortality figures do not. Yet the provisional mortality figures for cancer are above the past figures. The problem is worse than these figures suggest. Let’s review: we have injections that were approved without carcinogenicity testing. We now have a spike in cancer. Can you please show me where you have investigated this spike and ruled out it being from the COVID injections? Have you even considered that?
Prof. Murphy: There is no evidence that increase in cancer risk is vaccine-associated. As Professor Langham said, there have been many billions of doses of these vaccines administered. If there was a significant association with cancer, I think the international data would have shown it. There is no evidence that there is an association.
Senator ROBERTS: The reference to lipid nanoparticles in earlier conversations around COVID vaccines suggested that the nanoparticles stayed near the injection site, then passed out of the body. Am I remembering that correctly?
Dr Langham: Senator, that’s correct. We’ve dealt with this on a number of occasions, in answer to other questions on notice as well.
Senator ROBERTS: Documents released in the Pfizer-gate court-ordered document dump showed that Pfizer knew at the time of seeking approval for their product that the lipid nanoparticles not only collected at the injection site but significant concentrations were also recorded in the adrenal glands. A table in the Pfizer test data showed they accumulated in the ovaries, the liver, the kidneys, the brain and the adrenal glands; they go all over the body. Did you know at the time of the Pfizer application that lipid nanoparticles collected across the body?
Dr Langham: Senator Roberts, what you are describing is a particular aspect of the pre-clinical studies by which an element of the lipid nanoparticles was labelled with a fluorescent label. What is seen in those studies is the fluorescent label and not necessarily the lipid nanoparticles.
Senator ROBERTS: Is it still your position that this build-up does not have an adverse health effect?
Dr Langham: Correct.
Senator ROBERTS: Why did former minister Greg Hunt say, ‘The world is engaged in the largest clinical vaccination trial’? Why did he say that as health minister?
Dr Langham: I can’t speak for Minister Hunt’s comment; I am sorry.
Senator ROBERTS: We have dealt with other agencies and employers who relied on you, as the TGA. They cite your advice as the basis of their policies and decisions: CASA, the Civil Aviation Safety Authority, Fair Work Commission, Fair Work Ombudsman, Department of Employment and Workplace Relations, judiciary, the Department of Home Affairs, the Department of Agriculture, Fisheries and Forestry, the NSW Council for Civil Liberties, state and federal health ministers, the chief medical officer and the chief health officer all drove vaccine mandates. The national cabinet cited you guys. Millions of people have been gutted, based on these horrendous facts and injuries, all pointing their finger at you. Do the members of the board of the TGA understand the concept of misfeasance in public office?
Prof. Murphy: There is no board of the TGA. The TGA is part of the department of health.
Senator ROBERTS: Do the heads of the TGA understand the concept of misfeasance?
Prof. Murphy: We very much understand the concept of misfeasance, and we totally reject any suggestion that has taken place. I should point out that the TGA has never taken a position on vaccine mandates. The TGA’s remit is to assess the safety and efficacy.
Senator ROBERTS: Do you support them or not?
Prof. Murphy: The Commonwealth department has supported them in limited circumstances, particularly early on, when transmission reduction was much more beneficial. We certainly supported them for aged-care workers and disability workers. The Commonwealth department has not taken a strong position on community-wide mandates. Some of the state and territory governments have taken a much stronger position.
Senator ROBERTS: Who from your senior leadership advised former Prime Minister Scott Morrison to buy the injections, at billions of dollars, to then give them to the states, to indemnify the states, to also then provide the health monitoring data so that vaccine mandates could be introduced? The state premiers then said that they mandated vaccines on the basis of the national cabinet, which the Chief Medical Officer is associated with. Then we saw the former Prime Minister mandate vaccines in Defence, the Australian Electoral Commission and aged care. Then the former Prime Minister said repeatedly, daily, for two weeks, ‘We have no vaccine mandates in this country.’ It was a blatant lie. Did you do anything to stop him lying?
Prof. Murphy: I can’t comment on what the former Prime Minister said. I know he supported vaccine mandates in aged care and disability. That was very much a national cabinet position because of the high vulnerability of the residents and workforce in those settings. I don’t believe national cabinet took a community-wide mandate approach. Various agencies—state, territory, Commonwealth and private sector agencies—made their own decisions about that. I don’t think it is fair to say that the TGA has been promoting vaccine mandates. It’s not their remit and they have never done it.
Senator ROBERTS: Did you do anything to stop it?
CHAIR: Thank you, Professor Murphy. Senator Roberts, I do need to share the call. Are you able to place the remainder of your questions on notice at this point?
A cheap, safe, award-winning, generic medicine, one that has been around for decades and was readily available, was shown to save people’s lives during an outbreak of a virus. Do you think it was a good decision for Australia’s Therapeutic Drug Administration (TGA) to arbitrarily ban its availability and off-label prescription in order to save it for skin conditions? Why not just buy more of it?
Despite substantial bodies of evidence from around the world, Australia did not recognise the available proof supporting Ivermectin’s use because no ‘sponsor’ (read pharmaceutical company) brought it to the TGA. What they did do was convene a Commonwealth-funded Clinical Evidence ‘Kangaroo Court’ which declared Ivermectin had no value in the treatment or prevention of COVID19.
This completely ignored a generation of evidence that Ivermectin was an effective early stage treatment for coronavirus.
The TGA continued to ignore the new data that showed Ivermectin was an effective and safe early treatment for COVID until the jab rate was over 95%, then they allowed its use. Here’s the kicker — the TGA admits in this video they made this decision because they were worried that people would not seek vaccination if they believed Ivermectin could help them.
Regulatory capture by pharmaceutical industries is a well known concept but I’m reassured that this “doesn’t happen at the TGA”. Yet in the same line of questioning, the TGA admits that if a pharmaceutical company sponsor does not promote a drug with them, and pay the fee of course, they don’t bother to show the initiative themselves.
This is purely a transactional process, as the TGA itself admits in this senate estimates. It’s clear that there is something very wrong with the system.
Transcript
Senator ROBERTS: My questions are to the TGA. In the last Senate estimates, I asked Adjunct Professor Skerritt if the TGA was inquiring into the opportunity presented by albicidin, a natural antibacterial derived from a sugarcane virus that does not cause antimicrobial resistance. Dr Skerritt’s response was: We are very closely monitoring the science. In fact, I’m the keynote speaker next Thursday at the Australian Antimicrobial Congress…We haven’t had a submission relating to that product because it’s still very early days, but we are monitoring…antimicrobial resistance because…it’s a serious threat.
I was concerned that was a non-answer, so I asked the minister about it, in question on notice 1449. His response was: ‘The department of health is not conducting a review into albicidin.’ Can you clear this up, please? Are you treating albicidin as a prospective revelation in the battle against antimicrobial resistance, thoroughly deserving of active research and development?
Dr Langham: The normal manner in which the TGA evaluates and assesses a product for use is through a process whereby a sponsor brings us a product, with all of the relevant research, clinical trials and a dossier of its safety and quality, and that has not happened at this stage. Until someone comes to us with this, we’re not able to do anything in terms of furthering what could potentially be a really important treatment; we’re not able to further that, in terms of making it available to the public.
Senator ROBERTS: Does the department of health have any role, ability or authority to sponsor?
Prof. Murphy: Generally, no. Occasionally, we have taken the role of sponsoring in very difficult circumstances, when there’s a drug that’s registered and available and the sponsor doesn’t want to sponsor it. But with an experimental new drug, we would never take that role. Occasionally, there are avenues for us to support drug development through MRFF and NHMRC research. There have certainly been programs that have looked at therapeutic advances in that space. But with a new agent or a new molecule, it would be quite inappropriate for us to take a role as a sponsor.
Senator ROBERTS: The TGA is 96 per cent funded by pharmaceutical companies through fees. Albicidin is a naturally occurring substance. Can it be patented? I would say not.
Prof. Murphy: We’d have to take that on notice. It depends on the use, and patent law is quite complicated. I can’t answer that.
Senator ROBERTS: My point is: would it get a sponsor to make an application? Drug companies rely a lot on patents and making excessive profits.
Dr Langham: You would expect so, absolutely.
Prof. Murphy: If it were proven to be highly effective, I would imagine that a drug company would be very interested in pursuing it, but—
Senator ROBERTS: Drug companies have shown that they’re only interested in profits—the major ones.
CHAIR: Please put that as a question, Senator Roberts.
Senator ROBERTS: Yes, it is a question.
CHAIR: What was the question?
Senator ROBERTS: Isn’t that the case?
Prof. Murphy: No. Private companies all make a profit, but profits can often come by sponsoring highly effective new agents; that’s where they make their biggest profits. This is all highly speculative and I don’t know that we can progress it much further.
Senator ROBERTS: The CSIRO has produced a guide to controlling antimicrobial resistance that assumes massive government power, including close monitoring and regulation of homes, pets, agriculture, waterways, new vaccines against diseases that used to be controlled by antibiotics and, of course, conferences. Antimicrobial resistance is being set up to be a massive government and pharmaceutical company gravy train. Why are you ignoring a probable solution to antimicrobial resistance? Do you want the power to order more vaccines, to wield more intrusive powers and to make more sales for big pharma, which is the history of the last few years?
Prof. Murphy: We reject that assertion. We completely accept the assertion that antimicrobial resistance is a significant problem. One of the ways that we have been, for many years, trying to combat it is to try to encourage prescribers in the use of antibiotics to reduce their use of antibiotics, which is not in the interests necessarily of the pharmaceutical industry. We are very keen to make sure that we limit the use of antibiotics to those situations where they are absolutely essential. There’s a lot of unnecessary prescription of antibiotics, and some of that is a real problem. We certainly have a lot of interest in antimicrobial resistance, and any new agent would be of interest to us. But we are not in a position to sponsor something like that.
Ms Duffy: We are in collaboration with the CSIRO in advancing their work and we have been involved in a number of CSIRO roundtables on this project that they’re going through, so we are working in lockstep with them.
Senator ROBERTS: Let’s turn to medical or medicinal cannabis. My office is getting reports that prescriptions of dried medical cannabis issued under the pathways scheme are being endorsed with the phrase ‘for vaping’, and that requires patients to also buy and use a vape. A doctor that my office spoke to has advised that this is a TGA instruction; is that correct?
Dr Langham: Medicinal cannabis products, with the exception of two of them, are not regulated as ‘medicinal products’ by the TGA. They are available under a special access scheme, and it’s a condition of the special access scheme that the practitioner who is approved to prescribe adopts all of the undertaking to ‘consent’ patients, to understand the research, to advise on side effects and so forth. The TGA does not regulate any of the medicinal cannabis products in Australia.
Senator ROBERTS: Do you require someone who uses medical cannabis in dried form to purchase a vape— the device?
Dr Langham: It’s not our advice, no, and it would be coming from the medical practitioner, if the medical practitioner felt that there was a substance that was better done as an ointment, a tablet, a spray or a vape. I don’t know whether you’re able to add anything on vaping devices for that.
Ms Duffy: In terms of the method of delivery, it would be up to the treating practitioner to identify the most appropriate method for that patient.
Senator ROBERTS: To list a product under the Australian Register of Therapeutic Goods for prescription under schedule 4, there’s a prescribed process, which is not legislative. The steps, time frames and levels of proof of safety are all in regulation issued by the secretary under delegated powers, and much of the process isn’t even regulatory but administrative. Is that an accurate statement?
Dr Langham: I’d need help on what’s in the act and what’s in the regulations.
Dr Gilmour-Walsh: I didn’t understand all elements of that question.
Senator ROBERTS: Do you want me to repeat it?
Dr Gilmour-Walsh: Yes.
Senator ROBERTS: To list a product under the Australian Register of Therapeutic Goods for prescription under schedule 4, there’s a prescribed process, which is not legislative. The steps, time frames and levels of proof of safety are all in regulation issued by the secretary under delegated powers, and much of the process isn’t even regulatory but administrative. Is that an accurate statement?
Dr Gilmour-Walsh: I don’t know that’s an entirely accurate statement. Some of the process is set out in primary legislation and some of it is set out in delegated legislation. But, yes, there are some administrative policies that support the administration of the act.
Senator ROBERTS: Does the suspension of these processes by the minister and/or the secretary during COVID prove that the ARTG—the Australian Register of Therapeutic Goods—process is whatever the secretary or the minister says that it is?
Dr Gilmour-Walsh: That’s simply not the case. The secretary’s powers are bounded by the act and instruments made under the act, including regulations, which are made by the Governor-General.
Senator ROBERTS: COVID vaccines were not manufactured under good manufacturing process, GMP, so even this basic requirement for the approval of a drug is just a preference and not a legislated requirement, is it not?
Mr Henderson: For the provisional approvals of the vaccines, they needed to provide evidence that they were manufactured under good manufacturing practices.
Senator ROBERTS: But they weren’t. Could you get us a copy of that evidence, please?
Mr Henderson: I’ll have to take that on notice.
Senator ROBERTS: Yes, fine. Referencing section 26BF of the Therapeutic Goods Act 1989, this ‘allows the minister to direct the operations of the secretary in respect of the scheduling and listing of products’. Minister, isn’t it true that the minister could down-schedule medicinal cannabis to schedule 4 and move the products approved for prescription under the pathways program onto the Australian Register of Therapeutic Goods right now, if he wanted to? He might not intend doing that, but it is within the minister’s power, isn’t it?
Senator McCarthy: I’ll take that on notice.
Senator ROBERTS: I understand that the minister could regulate right now to move medicinal cannabis to schedule 4. Thank you, Minister.
CHAIR: I believe that the witness is taking that on notice; is that right?
Dr Gilmour-Walsh: Yes. We can take it on notice, but I’ll just add that I don’t believe that power supports that. The usual process is that there has to be a legislative instrument, made under a power much further down in the act, to amend the Poisons Standard.
Senator ROBERTS: The way that I’ve been advised, I’m pretty confident that it’s just a ministerial regulation.
Dr Gilmour-Walsh: We can consider that further, but that’s not my general understanding.
Senator ROBERTS: Minister, my office checked all the state legislation on prescribing and found much commonality. There is the use of a simple statement such as ‘prescriptions can be issued for anything listed in schedule 4′. There is no separate state list of drugs. If medicinal cannabis were down-scheduled federally, the states would need to introduce legislation to over-rule that decision and then get that legislation through their own parliament; is that correct?
Senator McCarthy: I’ll take that question on notice.
Senator ROBERTS: Thank you. Minister, could the bill introduced by Senator Hanson to down-schedule medicinal cannabis be regulated right now, today, if the minister chose to do so? In other words: the legislation is not needed and the minister could just regulate.
Senator McCarthy: I’ll take that on notice.
Senator ROBERTS: Thank you. Let’s come back to today. Today is a wonderful day to celebrate. Today is 1 June 2023. From 1 June 2023, the prescribing of oral ivermectin for off-label uses will no longer be limited to specialists such as dermatologists et cetera. It’s back and can be used off-label. I must note, to keep the secretary calm, that the TGA says that it does not endorse off-label prescribing of ivermectin for the treatment and prevention of COVID-19. It doesn’t do that, but it can be used for that. Craig Kelly, a former member of parliament, contacted the office of the chief minister in Uttar Pradesh—Uttar Pradesh is a state in India—and asked for guidance on how Uttar Pradesh had successfully used ivermectin to control the COVID virus in Uttar Pradesh. He received great information on their success. If a member of parliament, at the time, could reach out like that to be better informed, why didn’t the TGA reach out and be better informed on ivermectin?
Prof. Murphy: The TGA relies on the body of scientific evidence. Professor Langham can talk about that. We rely on the published scientific evidence and not the statement of a politician in India. Professor Langham, do you want to comment?
Dr Langham: Thank you. I guess it comes back to my earlier point that a drug, a medicine or a product that is on the ARTG is there for a specific indication. In this case, the specific indication for ivermectin—for which there’s been a dossier provided, evaluated by the TGA as robust, good clinical science—is that it is useful for the treatment of certain parasitic illnesses, be they gastrointestinal or skin based. No evidence has been presented to the TGA by the sponsor to demonstrate in any way, shape or form that ivermectin is useful in treating COVID-19. If the sponsor would like to do so, we’d be happy to consider that, because that’s the only way that the TGA is able to expand that indication.
Senator ROBERTS: Could I table these for discussion, please, Chair.
CHAIR: You can submit them to the committee for consideration. It’s going to take a while to work through them, by the look of it.
Senator ROBERTS: What is being distributed is an affidavit from Dr Pierre Kory in the United States. He has gone through this for many years and he has compiled many references—I think it’s over 96—that praise ivermectin’s use in treating COVID. It’s been used in many countries and has stopped COVID in its tracks. It has been not only a treatment but also a prophylactic, to prevent the spread of the disease. This is my last question: are you aware of any successful programs overseas that used ivermectin to control the pandemic? Now you’ve got the evidence, Professor Langham.
Dr Langham: Obviously, there’s a very dense article here and a lot of different publications are being referenced. For me to pass judgement on this particular body of evidence, I’d need to take that on notice and get back to you.
Senator ROBERTS: I’m pleased to hear you say that, because I wouldn’t want it done on the spur of the moment.
https://img.youtube.com/vi/792LxTu1Tgs/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2023-10-09 10:19:212023-10-09 10:21:57TGA is Risking Your Health to Act as a Sales Agent for Big Pharma
At the June Senate Estimates I asked several questions of the Therapeutic Goods Association (TGA).
I asked what the TGA was doing to help Australians access a potential new antibacterial to overcome antimicrobial resistance, medicinal cannabis, and off-label Ivermectin. What this trio of medicines has in common is that they are not profitable for pharma because, in the case of the first two, they cannot be patented and patents are how pharma makes its $billions.
Ivermectin is an award-winning drug with a huge body of evidence supporting both its anti-parasitic and anti-viral activity. Because it’s been around for over 70 years, is off-patent and inexpensive, there is little interest from pharma in sponsoring the drug. See how it works? These medications should not be left behind because of pharmaceutical company profit margins.
From the answers provided by the TGA, it’s clear that health products that don’t add to the wealth of pharmaceutical companies have no chance of approval under this Government. The TGA should be acting in the best interests of the Australian people, not the profit margins of big pharma.
Transcript
Senator Roberts: Given the backflip, Mr Fletcher, by the TGA that now allows the prescribing of ivermectin, which can be used off label as treatment for COVID—the TGA makes it clear that it does not endorse it as a treatment but now allows it as a treatment for COVID—what is the attitude of Ahpra towards those doctors now who were cast aside because they supported ivermectin?
Mr Fletcher: Any regulatory action we have taken or would take in relation to a health practitioner would always take account of the public health advice at the time that the alleged concern occurred.
Senator Roberts: The public advice was wrong.
Mr Fletcher: It would be on the basis of the advice that was in place at the time.
Senator Roberts: Isn’t it strange that ivermectin started off as a highly regarded, very safe drug, given in four billion doses around the world, and then we were told that it was a dangerous drug, and now it’s remarkably safe again with a worldwide profile of being a safe treatment for COVID-19?
Prof. Murphy: Senator, I do have to intervene. There is no change. There is no recommendation that ivermectin be used for COVID. The regulatory changes—
Senator Roberts: I didn’t say that. I said to the contrary. I said the TGA does not endorse them.
Prof. Murphy: No, it’s not—
Senator Roberts: I did not say that there was an endorsement.
Prof. Murphy: No, there isn’t an endorsement. But the change in the regulation has nothing to do with any change in its efficacy or otherwise for COVID simply to reflect the changing circumstances and there’s no need to keep what’s a very unusual restriction on a drug. The TGA as decided it’s no longer proportionate, but there’s still no evidence of any value.
Senator Roberts: So what changed with the TGA?
Prof. Murphy: What changed with the TGA? We’ll get the TGA to address that.
Senator Gallagher: They’re due this evening.
Senator Roberts: Okay. Ahpra never did its own research on the COVID injections and relied on what it was told by the TGA. You said that a little while ago. The TGA never did its own research. In answering a question that I put to them at the last estimates it relied instead on what it was told by the FDA. It has never assessed the patient-level data.
Prof. Murphy: This is not a question for Ahpra.
Senator Roberts: I’m getting to that.
Chair: Senator Roberts, could you put it as a question?
Senator Roberts: Are you aware that the TGA, which you rely on, has never assessed the patient-level data.
Mr Fletcher: As I said earlier, the sources of public health advice to us are the TGA, ATAGI and the public health officials in each state and territory and the Commonwealth health department.
Senator Roberts: Are you aware that the TGA relied on the FDA and that the FDA itself, in America, never did its own research and relied simply on what Pfizer told it? According to its own records, Pfizer only ever did limited research and knew the vaccines injections were of limited value and had a significant risk profile. Pfizer lied when it said the vaccines were safe and effective, and Ahpra peddled this lie. You enforced that lie.
Chair: Senator Roberts, this is not a question. It’s very hard for me to maintain order if you don’t put questions.
Senator Roberts: Are you aware of the facts that I’ve just said about Pfizer? Are you aware of those facts?
Prof. Murphy: These are questions for the TGA. It’s not a question for Ahpra.
Senator Roberts: I want to know is he aware of what the TGA based their decision on?
Chair: Senator, if officials at the table indicate that this is not the appropriate place within the program to ask a question, we do need to respect that. My understanding of what Professor Murphy has said is that there is a time for these questions, and that is when we return to the TGA.
Senator Roberts: Thank you, Chair. I notice your silence. Why isn’t Ahpra aware of the false, fraudulent science underpinning the use of the vaccine?
Senator Gallagher: We don’t agree with that.
Senator Roberts: Thank you for answering, Minister. Why does Ahpra still support the use of the injections now that there is a body of respected, peer-reviewed science condemning the use of the so-called vaccines? Is it because the TGA—
Senator Gallagher: It’s not a matter for Ahpra.
Senator Roberts: How can so many deaths and serious injuries attributed to the vaccines continue to be ignored by Ahpra?
Prof. Murphy: Again, that is not a matter for Ahpra.
Senator Roberts: Ahpra are silent, okay.
Senator Gallagher: It’s not ‘silent’. It’s not a matter they have responsibility for. Witnesses come here to answer questions on areas they have responsibility for.
Senator Roberts: You’ve just taken responsibility for their response. That’s fine. Given that Ahpra—
Chair: Senator Roberts, we have dealt with this issue over the last few days. It is appropriate for the minister to respond to our questions put to the witnesses if that question is not put in the correct place or is not within that purview. It’s appropriate for Senator Gallagher to respond. Do you have another question, Senator Roberts?
Senator Roberts: Given that Ahpra is a board, I would suggest that board members are jointly responsible for the outcomes of their directions to health practitioners which now include the countless death and serious injuries that have befallen many otherwise healthy people who took the injections believing they were safe and effective, when they were not. Are you aware that board members will be culpable?
Senator Gallagher: They will not. It’s not their—
Senator Roberts: Can you give me the qualifications of every board member—their medical qualifications?
Senator Gallagher: I reject your assertions. I just want to be very clear. I’m not going to speak for everyone, but my position here is that we do not agree with the assertions you are continuously putting in this hearing.
Senator Roberts: That’s fine, Minister. I hear you. The board members—can you give me their qualifications, Mr Fletcher?
Prof. Murphy: The Ahpra board is a board that regulates the operations of the agency. The decisions around registration standards are made by the national boards, like the Medical Board, which is comprised of community and qualified practitioners. The board of Ahpra is simply a governance board of the bureaucratic operations of Ahpra. The decisions—
Senator Roberts: A governance board?
Prof. Murphy: It does not govern the regulatory decisions. Those decisions are made by the relevant professional national boards, as Mr Fletcher has pointed out on many occasions.
Senator Roberts: State bodies?
Prof. Murphy: National boards. There’s a national Medical Board, a national nursing board—
Senator Roberts: So why do we need Ahpra? They’re not accountable.
Prof. Murphy: Ahpra is the organisation that brings the work of those boards and sets up a national regulation system to enable practitioners to be regulated across the country. It is a means of bringing them together. This is professional registration, so each of those boards—
Senator Roberts: And deregistration. I’d like the qualifications, Mr Fletcher, on notice, of your board members, their qualifications in medicine, specifically what qualifications they have, and I’d like to know who appointed them. Can you take that on notice?
Prof. Murphy: It’s on the website.
Senator Gallagher: It is on the website, look it up. In relation to profession-specific, as Professor Murphy said, there is the Medical Board, which has representatives; there’s nursing; there’s a whole range of them. They used to be the state and territory boards; they came together to be national boards. They would have different representatives.
Senator Roberts: Can you tell me who appointed each of the members?
Mr Fletcher: The national board members are appointed by state, territory and Commonwealth health ministers.
Senator Roberts: And Ahpra?
Mr Fletcher: The Ahpra board is also appointed by state and territory health ministers and the Commonwealth health minister.
Chair: Thank you very much, Ahpra. We appreciate your favourable response to our request to join us at Senate estimates.
The Australian National Audit Office (ANAO) is thorough and does some fine work. Its audit of the National Emergency Management Agency (NEMA) and the National Recovery and Resilience Agency (NRRA) found performance accountability missing.
At Senate Estimates the ANAO audit of Disaster Recovery Funding uncovered several reporting deficits with NEMA and NRRA that need to be addressed, vindicating my previous call for a Senate Inquiry into the administration of Disaster Relief Funding Arrangements to expose the misuse funds.
I called for an ANAO audit of Coal LSL (Long Service Leave) after Chartered Accountants KPMG’s concerning report of Coal LSL revealed many governance problems and the non-paying of entitlements to Hunter Valley coal miners.
I’ve been raising these issues for the past four years and will keep raising them on behalf of Australians until these identified problems and governance issues are resolved.
ANAO has agreed to examine this so watch this space.
https://img.youtube.com/vi/M3xFslaCp58/maxresdefault.jpg7201280Sheenagh Langdonhttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSheenagh Langdon2023-09-02 07:09:142023-09-04 16:23:25Pursuing Accountability Among the Agencies
